| Budget Amount *help |
¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
|
|---|
| Outline of Final Research Achievements |
We confirmed that the demethylating agent (decitabine) enhances the cytotoxic effect of anti-leukemic agents such as clofarabine and etoposide synergistically, and the cytotoxic effect is depend on caspase-3/7 activity. Then, we confirmed that decitabine increase mRNA expression levels of BID, BAX, BAD, PUMA, CASP3. Although, decitabine did not demethylate the CpG of BID, BAX, BAD, CASP3. Therefore, we carried out genome-wide gene expression studies and epigenome-wide association studies. The results showed that decitabine demethylate the CpG of AATK and increase its mRNA expression.
|
